Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Beasley, C. M.
1999.
[No Title].
British Journal of Psychiatry,
Vol. 175,
Issue. 4,
p.
392.
Woods, S. W.
1999.
Olanzapine and tardive dyskinesia.
British Journal of Psychiatry,
Vol. 175,
Issue. 4,
p.
391.
Emsley, Robin A.
2000.
Role of Newer Atypical Antipsychotics in the Management of Treatment- Resistant Schizophrenia.
CNS Drugs,
Vol. 13,
Issue. 6,
p.
409.
Andreassen, Ole A.
and
Jørgensen, Hugo A.
2000.
Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats.
Progress in Neurobiology,
Vol. 61,
Issue. 5,
p.
525.
Turrone, Peter
Seeman, Mary V
and
Silvestri, Simone
2000.
Estrogen Receptor Activation and Tardive Dyskinesia.
The Canadian Journal of Psychiatry,
Vol. 45,
Issue. 3,
p.
288.
Catts, Stanley V.
O'Toole, Brian I.
and
Draganic, Daren M.
2000.
Editorial.
Australian & New Zealand Journal of Psychiatry,
Vol. 34,
Issue. 2_suppl,
p.
S1.
Catts, Stanley V.
O'Toole, Brian I.
and
Draganic, Daren M.
2000.
Editorial.
Australian and New Zealand Journal of Psychiatry,
Vol. 34,
Issue. (Suppl.),
p.
S1.
Duggan, L
Fenton, M
Dardennes, RM
El-Dosoky, A
and
Indran, S
2000.
Cochrane Database of Systematic Reviews.
Möller, Hans-Jürgen
2000.
Definition, Psychopharmacological Basis and Clinical Evaluation of Novel/Atypical Neuroleptics: Methodological Issues and Clinical Consequences.
The World Journal of Biological Psychiatry,
Vol. 1,
Issue. 2,
p.
75.
Catts, Stanley V.
O'Toole, Brian I.
and
Draganic, Daren M.
2000.
Editorial.
Australian & New Zealand Journal of Psychiatry,
Vol. 34,
Issue. 1_suppl,
p.
A1.
Tollefson, Gary D.
and
Taylor, Cindy C.
2000.
Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent.
CNS Drug Reviews,
Vol. 6,
Issue. 4,
p.
303.
Lund, Brian C
and
Perry, Paul J
2000.
Olanzapine: an atypical antipsychotic for schizophrenia.
Expert Opinion on Pharmacotherapy,
Vol. 1,
Issue. 2,
p.
305.
Morgenstern, Hal
Glazer, William M.
and
Woods, Scott W.
2001.
Risperidone and tardive dyskinesia.
International Journal of Geriatric Psychiatry,
Vol. 16,
Issue. 5,
p.
541.
Woods, Scott W.
Miller, Tandy J.
and
McGlashan, Thomas H.
2001.
The “Prodromal” Patient: Both Symptomatic and At-Risk.
CNS Spectrums,
Vol. 6,
Issue. 3,
p.
223.
Cookson, RF
2001.
The newer antipsychotics: evidence for cost-effectiveness and policy implications.
Journal of Medical Economics,
Vol. 4,
Issue. 1-4,
p.
63.
Oosthuizen, Piet
Emsley, Robin A.
Turner, Jadri
and
Keyter, Natasha
2001.
Determining the optimal dose of haloperidol in first-episode psychosis.
Journal of Psychopharmacology,
Vol. 15,
Issue. 4,
p.
251.
Rascol, Olivier
and
Fabre, Nelly
2001.
Dyskinesia: L-Dopa-Induced and Tardive Dyskinesia.
Clinical Neuropharmacology,
Vol. 24,
Issue. 6,
p.
313.
Carvajal, Alfonso
and
Martín Arias, Luis H.
2001.
Vol. 24,
Issue. ,
p.
53.
Kennedy, John S.
Bymaster, Frank P.
Schuh, Leslie
Calligaro, David O.
Nomikos, George
Felder, Christian C.
Bernauer, Mark
Kinon, Bruce J.
Baker, Robert W.
Hay, Donald
Roth, H. John
Dossenbach, Martin
Kaiser, Christopher
Beasley, Charles M.
Holcombe, John H.
Effron, Mark B.
and
Breier, Alan
2001.
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.
International Journal of Geriatric Psychiatry,
Vol. 16,
Issue. S1,
p.
S33.
MALONE, RICHARD P.
CATER, JACQUELINE
SHEIKH, ROOMANA M.
CHOUDHURY, MUNIYA S.
and
DELANEY, MARY ANNE
2001.
Olanzapine Versus Haloperidol in Children With Autistic Disorder: An Open Pilot Study.
Journal of the American Academy of Child & Adolescent Psychiatry,
Vol. 40,
Issue. 8,
p.
887.
eLetters
No eLetters have been published for this article.